Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003370 · ClinicalTrials.gov registry record · Phase 1
Irofulven in Treating Children With Recurrent or Refractory Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00003370: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00003370 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003370, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Phase I trial to study the effectiveness of irofulven in treating children with recurrent or refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells so they stop growing or die.
Interventions
- DRUG irofulven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 1998-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003370
The ClinicalTrials.gov registry entry for NCT00003370 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which irofulven is the first listed.
NCT00003370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003370 about?
NCT00003370 is a clinical study titled "Irofulven in Treating Children With Recurrent or Refractory Solid Tumors". Phase I trial to study the effectiveness of irofulven in treating children with recurrent or refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells so they stop growing or die.
What is the current status of trial NCT00003370?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 1998-08.
What interventions are being tested in trial NCT00003370?
The interventions under investigation include: irofulven (DRUG).
Who is sponsoring clinical trial NCT00003370?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.